Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor infiltrating lymphocytes GT101
- Development stage
- Phase 2
- Lead developer
- Suzhou Gravel Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GT101 is an investigational cell therapy consisting of autologous tumor-infiltrating lymphocytes (TILs) that are isolated from a patient's own tumor, expanded ex vivo, and then reinfused into the patient following a preparative lymphodepletion regimen and high-dose interleukin-2 (IL-2) administration. The infused TILs specifically recognize and kill the patient's tumor cells. In phase 1 clinical studies, GT101 demonstrated a manageable safety profile and encouraging clinical activity in patients with heavily pretreated advanced or metastatic solid tumors, particularly cervical cancer[1][2]. The therapy is being evaluated for its ability to induce objective responses in various solid tumors. Developed by: Suzhou Gravel Biotechnology
- Other names
- autologous tumor infiltrating lymphocytes GT101
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on autologous tumor infiltrating lymphocytes GT101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor infiltrating lymphocytes GT101.